Skip to main content

Table 1 Baseline characteristics

From: Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study

 

All Subjects

(n = 184)

Telmisartan40/S-Amlodipine2.5

(n = 96)

Telmisartan80

(n = 88)

P-value

Male (n, %)

105 (57.1)

59 (61.5)

46 (52.3)

0.209a)

Age, mean (year)

63.1 ± 11.7

63.5 ± 12.5

62.7 ± 10.9

0.650b)

Height (cm)

162.3 ± 8.6

163.0 ± 8.2

161.6 ± 9.0

0.270a)

Body weight (kg)

70.0 ± 13.8

69.6 ± 11.1

70.5 ± 16.3

0.650a)

HTN (n, %)

184 (100.0)

96 (100.0)

88 (100.0)

 

Duration of HTN, mean (year)

11.6 ± 9.1

12.0 ± 9.5

11.2 ± 8.6

0.580a)

DM (n, %)

65 (35.3)

33 (34.4)

32 (36.4)

0.778a)

Duration of DM (year)

8.0 ± 9.2

7.3 ± 7.4

8.8 ± 10.8

0.532b)

CKD (n, %)

34 (18.5)

18 (18.8)

16 (18.2)

0.921a)

Office SBP (mmHg)

153.1 ± 15.5

154.8 ± 16.0

151.2 ± 14.9

0.111a)

Office DBP (mmHg)

89.2 ± 11.9

88.9 ± 12.5

89.6 ± 11.4

0.677a)

Heart rate (bpm)

73.2 ± 12.6

72.6 ± 13.3

73.9 ± 11.7

0.486a)

Body temperature (°C)

36.5 ± 0.2

36.5 ± 0.2

36.5 ± 0.2

0.920a)

  1. a)Result of chi-square test. b) Result of Fisher’s exact for comparison between the two groups
  2. HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; SBP, systolic blood pressure DBP, diastolic blood pressure